Answers are grounded in this paper and cite their sources.
Early diagnosis of Dengue fever is critical for effective patient management and outbreak control. This study presents an electrochemical biosensor based on a mimetic peptide (MPDV) covalently immobilized on a gold electrode modified with reduced graphene oxide (r-GO) and poly(3-hydroxyphenylacetic acid). The sensing mechanism is based on the specific binding of anti-DENV IgM antibodies by the LLRNAST core epitope-mimicking recognition motif within the MPDV peptide. This biological interaction modulates the intrinsic electrooxidation of the peptide's cysteine residues, resulting in a sensitive label-free and mediator-free signal. Surface characterization by AFM, CV, and EIS confirmed the successful layer-by-layer assembly of the sensing interface and effective peptide immobilization. The r-GO/poly(3-HPA) nanocomposite promoted a 19-fold enhancement of the electroactive charge, significantly increasing sensitivity. Molecular dynamics simulations demonstrated stable peptide orientation, ensuring the accessibility of the binding motif. The biosensor exhibited a linear response toward anti-DENV IgM in human serum over the dilution range from 1:50 to 1:10,000, with a correlation coefficient (R 2 ) of 0.999. The limit of detection (LOD) was 0.30 ng·mL -1 and the limit of quantification (LOQ) was 0.99 ng·mL -1 . Selectivity was validated against symptomatic negative controls and co-circulating flaviviruses, supported by preliminary immunoassay data, demonstrating negligible non-specific interactions. The biosensor retained approximately 91% of its initial response after 40 days of storage under dry storage at 8 °C. By integrating a structurally stable mimetic peptide with a nanostructured conductive interface, this study establishes a highly sensitive strategy for selective anti-DENV IgM detection. The combination of experimental and theoretical modeling provides a robust platform for early dengue diagnosis and highlights the potential of this mediator-free biosensor for point-of-care applications.
No takes yet. Share an insight, caveat, or question.
Vieira et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: